Skip to main content

Table 2 Percent of Patients with an Increase in Dose After One Year

From: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

 

Infliximab

Etanercept

 
 

Patients with 3+ infusions

Pct with an increase in dose

Patients with 3+ infusions

Pct with an increase in dose

p-value

Overall

598

57.9%

950

18.1%

<0.001

by Pre-period RA Costs

     

Quartile 1 – $0 to $502.89

157

49.7%

230

16.5%

<0.001

Quartile 2 – $502.90 to $975

157

62.4%

230

18.7%

<0.001

Quartile 3 – $975.15 to $176

135

57.8%

252

15.9%

<0.001

Quartile 4 – $1766.22 +

149

61.7%

238

21.4%

<0.001

by Year

     

1999*

0

0.0%

196

22.4%

<0.001

2000

309

53.1%

602

17.9%

<0.001

2001

289

63.0%

152

13.2%

<0.001

by Region

     

East

52

53.8%

149

20.1%

<0.001

South

269

60.2%

151

17.2%

<0.001

Midwest

232

57.3%

545

19.4%

<0.001

West

45

51.1%

105

9.5%

<0.001

by Age Group

     

< 18 Years

1

100.0%

39

33.3%

<0.001

18 – 34 Years

42

50.0%

83

14.5%

<0.001

35 – 44 Years

119

66.4%

221

16.7%

<0.001

45 – 54 Years

214

60.3%

353

17.3%

<0.001

55 – 64 Years

194

54.1%

238

18.9%

<0.001

65 + Years

28

39.3%

16

25.0%

<0.001

  1. *Infliximab dosing for RA was not detectable via HCPCS code until June of 2000
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us